Parabilis Medicines (PBLS) director converts Series F preferred into common in IPO

Rhea-AI Filing Summary

Parabilis Medicines director Alexis Borisy converted preferred stock into common shares tied to the company’s IPO. On June 11, 2026, 162,221 shares of Series F Preferred Stock were converted into 105,414 shares of Common Stock, leaving him with 105,414 common shares directly owned. According to the terms, each preferred share converted at a 1 to 0.6498 rate and automatically converted into common shares immediately before the closing of the initial public offering on June 9, 2026. This was a non-cash derivative conversion, not an open‑market purchase or sale.

Insider Trade Summary

162,221 shares exercised/converted

Mixed 2 txns

Insider Borisy Alexis

Role null

Type	Security	Shares	Price	Value
Conversion	Series F Preferred Stock	162,221	$0.00	--
Conversion	Common Stock	105,414	$0.00	--

Holdings After Transaction: Series F Preferred Stock — 0 shares (Direct, null); Common Stock — 105,414 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Common shares acquired: 105,414 shares Preferred shares converted: 162,221 shares Conversion ratio: 1 to 0.6498 +2 more

5 metrics

Common shares acquired 105,414 shares Common Stock held directly after June 11, 2026 conversion

Preferred shares converted 162,221 shares Series F Preferred Stock converted into Common Stock

Conversion ratio 1 to 0.6498 Series F Preferred Stock into Common Stock basis

Exercise/Conversion count 1 transaction Derivative conversion event in transaction summary

IPO conversion date June 9, 2026 Automatic conversion immediately prior to IPO closing

Key Terms

Conversion of derivative security, Series F Preferred Stock, initial public offering, Common Stock

4 terms

Conversion of derivative security financial

"transaction_code_description: Conversion of derivative security"

Series F Preferred Stock financial

"security_title: Series F Preferred Stock"

Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.

initial public offering financial

"immediately prior to the closing of the Issuer's initial public offering on June 9, 2026"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

Common Stock financial

"was convertible into Common Stock on a 1 to 0.6498 basis"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borisy Alexis

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		C		105,414	A	(1)	105,414	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series F Preferred Stock	(1)	06/11/2026		C		162,221		(1)	(1)	Common Stock	105,414	(1)	0	D

Explanation of Responses:

1. Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Parabilis Medicines (PBLS) director Alexis Borisy report in this Form 4?

Alexis Borisy reported converting Series F Preferred Stock into Common Stock. On June 11, 2026, 162,221 preferred shares became 105,414 common shares through an automatic conversion linked to Parabilis Medicines’ initial public offering on June 9, 2026.

How many Parabilis Medicines (PBLS) common shares does Alexis Borisy hold after the conversion?

After the reported transactions, Alexis Borisy directly holds 105,414 shares of Parabilis Medicines Common Stock. These shares resulted from the automatic conversion of his Series F Preferred Stock in connection with the company’s initial public offering on June 9, 2026.

What was converted in the Parabilis Medicines (PBLS) Form 4 filing?

The filing shows a conversion of 162,221 shares of Series F Preferred Stock into 105,414 Common Stock shares. This was recorded as a derivative conversion, coded “C,” and represents a change in security type rather than a market purchase or sale.

What is the Series F Preferred Stock conversion ratio at Parabilis Medicines (PBLS)?

Each share of Parabilis Medicines Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis. This fixed ratio determined how many common shares were received when the preferred shares automatically converted around the initial public offering closing.

How is the Parabilis Medicines (PBLS) IPO related to this insider transaction?

The footnote explains the preferred shares automatically converted into Common Stock immediately before the closing of Parabilis Medicines’ initial public offering on June 9, 2026. The Form 4 records this IPO‑related capital structure change for director Alexis Borisy.